tldrdaily.news logo
Tag

Astellas Pharma

All articles tagged with #astellas pharma

healthcare2 years ago

Advancements in Bladder Cancer Treatment Revolutionize Standard of Care

The combination of Seagen and Astellas Pharma's Padcev with Merck's Keytruda has been hailed as the "new standard of care" in first-line bladder cancer, according to confirmatory trial data presented at the European Society for Medical Oncology (ESMO) conference. The combination therapy demonstrated significantly improved overall survival and progression-free survival compared to chemotherapy, potentially expanding the eligible patient population.

via Endpoints News|
#astellas-pharma#bladder-cancer#healthcare
health2 years ago

FDA approves new drug for menopausal hot flashes.

The FDA has approved a new once-a-day pill, Veozah, from Astellas Pharma to treat moderate-to-severe hot flashes caused by menopause. The drug uses a new approach, targeting brain connections that help control body temperature. More than 80% of women experience hot flashes during menopause, but the most common treatment, hormonal pills, isn't appropriate for some women. The new pill is not a hormone and carries an FDA warning about potential liver damage. It will cost $550 for a one-month supply before insurance coverage and other discounts.

via WJW FOX 8 News Cleveland|
#astellas-pharma#fda#health
health2 years ago

FDA approves new pill for menopausal hot flashes.

The FDA has approved Veozah, the first nonhormonal medication to treat hot flashes in menopausal women. The drug targets a neuron in the brain that becomes unbalanced as estrogen levels fall and is cleared for moderate to severe symptoms. Hormonal treatments including estrogen and progestin were linked to elevated risks of blood clots and strokes decades ago. The drug would cost $550 for a 30-day supply, not including rebates, and would be available in pharmacies within three weeks of approval.

via The New York Times|
#astellas-pharma#fda#health
business2 years ago

Astellas Pharma acquires Iveric Bio for $5.9 billion.

Astellas Pharma has agreed to acquire US drugmaker Iveric Bio for $5.9bn, its biggest acquisition to date, giving it access to a range of ophthalmology treatments. The deal is the fifth major overseas acquisition by Astellas since 2019 in a push to shore up its pipeline as its main sellers lose patent protection. Iveric is focused on developing treatments for retinal diseases, with its key asset being avacincaptad pegol (ACP), currently in trials for treating geographic atrophy, the advanced stage of macular degeneration.

via Reuters|
#acquisition#astellas-pharma#business
politics2 years ago

Japan's PM demands release of detained businessman in China amidst strained relations.

Japan's Prime Minister Fumio Kishida has demanded the release of an Astellas Pharma employee detained in China, as fears remain over the safety of China's business environment. The lack of clarity over what prompted the detainment has left other Japanese business people on edge. The detained Astellas employee has worked in China for over 20 years.

via Reuters.com|
#astellas-pharma#business-environment#china
politics2 years ago

Japan demands release of detained citizen accused of spying in China

Japan has demanded China release one of its nationals, an employee of drug-maker Astellas in his 50s, who has been detained since early March on allegations of espionage. China has detained at least 17 Japanese nationals for alleged espionage since 2015. Relations between the two countries have long been strained over the disputed East China Sea islands, wartime history and Taiwan. China confirmed that the man was being held for espionage and said it would handle the case in accordance with law. Astellas Pharma confirmed that the man was its employee but refused to divulge his identity.

via BBC|
#astellas-pharma#china#diplomacy